Verona Pharma PLC American Depositary Share (NASDAQ:VRNA) was downgraded by Zacks Investment Research from a “buy” rating to a “hold” rating in a research report issued on Tuesday.

According to Zacks, “Verona Pharma plc is a clinical-stage biopharmaceutical company. It researches, discovers and develops therapeutic drugs to treat respiratory diseases primarily in the United Kingdom and North America. Verona Pharma plc is based in London, the United Kingdom. “

A number of other research firms have also recently weighed in on VRNA. SunTrust Banks, Inc. began coverage on shares of Verona Pharma PLC American Depositary Share in a report on Monday, May 22nd. They set a “buy” rating and a $26.00 price objective on the stock. Wedbush began coverage on shares of Verona Pharma PLC American Depositary Share in a research report on Monday, May 22nd. They set an “outperform” rating and a $25.00 target price on the stock. Jefferies Group LLC restated a “buy” rating and set a $26.00 target price on shares of Verona Pharma PLC American Depositary Share in a research report on Monday, May 22nd. Finally, Stifel Nicolaus began coverage on shares of Verona Pharma PLC American Depositary Share in a research report on Monday, May 22nd. They set a “buy” rating and a $22.00 target price on the stock. One analyst has rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. Verona Pharma PLC American Depositary Share currently has a consensus rating of “Buy” and a consensus price target of $22.60.

Verona Pharma PLC American Depositary Share (NASDAQ VRNA) traded up 2.2072% during mid-day trading on Tuesday, reaching $12.2342. 4,938 shares of the company’s stock traded hands. The stock’s 50 day moving average is $14.21 and its 200-day moving average is $14.01. The stock’s market capitalization is $78.54 million. Verona Pharma PLC American Depositary Share has a 52 week low of $11.03 and a 52 week high of $17.50.

TRADEMARK VIOLATION NOTICE: “Verona Pharma PLC American Depositary Share (VRNA) Downgraded by Zacks Investment Research to Hold” was first posted by American Banking News and is the property of of American Banking News. If you are viewing this piece on another website, it was illegally stolen and reposted in violation of U.S. & international copyright legislation. The original version of this piece can be viewed at https://www.americanbankingnews.com/2017/08/08/verona-pharma-plc-american-depositary-share-vrna-downgraded-by-zacks-investment-research-to-hold.html.

An institutional investor recently bought a new position in Verona Pharma PLC American Depositary Share stock. Vivo Capital LLC bought a new position in Verona Pharma PLC American Depositary Share (NASDAQ:VRNA) during the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund bought 704,225 shares of the company’s stock, valued at approximately $8,208,000. Verona Pharma PLC American Depositary Share comprises 2.1% of Vivo Capital LLC’s investment portfolio, making the stock its 11th largest position. Vivo Capital LLC owned about 10.97% of Verona Pharma PLC American Depositary Share at the end of the most recent quarter. Institutional investors own 5.09% of the company’s stock.

About Verona Pharma PLC American Depositary Share

Verona Pharma plc, a clinical stage biopharmaceutical company, researches, discovers, and develops therapeutic drugs to treat respiratory diseases primarily in the United Kingdom and North America. The company’s lead product is RPL554, an inhaled dual inhibitor of the enzymes phosphodiesterase 3 and 4, which is in Phase IIa clinical trial that acts as a bronchodilator and an anti-inflammatory agent for the treatment of chronic obstructive pulmonary disease, cystic fibrosis, and asthma.

Get a free copy of the Zacks research report on Verona Pharma PLC American Depositary Share (VRNA)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Verona Pharma PLC American Depositary Share Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Verona Pharma PLC American Depositary Share and related companies with MarketBeat.com's FREE daily email newsletter.